A

    AN2 Therapeutics Inc (ANTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.55
    -0.03 (-0.54%)

    Market Cap: $210.57M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(10/18)
    Avg Surprise
    -27.45%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.26
    Range$-0.27 - $-0.24
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.22+13.7%
    60d ago$-0.24+5.9%
    30d ago$-0.24+5.9%
    7d ago$-0.24+5.9%
    Current$-0.26
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.17
    Range$-0.20 - $-0.14
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.17---
    Sep 26EST
    		-$-0.26---
    Jun 26
    Reported Aug 6
    		$-0.18$-0.24+25.00%Beat+14.3%
    Mar 26
    Reported May 11
    		$-0.29$-0.23-26.09%Miss+17.1%
    Dec 25
    Reported Mar 17
    		$-0.29$-0.24-20.83%Miss-16.0%
    Sep 25
    Reported Nov 12
    		$-0.31$-0.22-40.91%Miss+11.4%
    Jun 25
    Reported Aug 12
    		$-0.21$-0.31+32.26%Beat+56.3%
    Mar 25
    Reported May 13
    		$-0.35$-0.27-29.63%Miss+37.5%
    Dec 24
    Reported Mar 25
    		$-0.25$-0.27+7.41%Beat+56.1%
    Sep 24
    Reported Nov 13
    		$-0.35$-0.39+10.26%Beat+46.2%
    Jun 24
    Reported Aug 13
    		$-0.48$-0.59+18.64%Beat+40.7%
    Mar 24
    Reported May 14
    		$-0.56$-0.62+9.68%Beat+29.1%
    Dec 23
    Reported Mar 28
    		$-0.57$-0.75+24.00%Beat+6.6%
    Sep 23
    Reported Nov 9
    		$-0.65$-0.63-3.17%Miss-10.2%
    Jun 23
    Reported Aug 10
    		$-0.81$-0.85+4.71%Beat-52.8%
    Mar 23
    Reported May 11
    		$-0.79$-0.68-16.18%Miss+73.5%
    Dec 22
    Reported Mar 29
    		$-0.61$-0.65+6.15%Beat-
    Sep 22
    Reported Nov 9
    		$-0.59$-0.60+1.67%Beat-
    Jun 22
    Reported Aug 11
    		$-0.53$-0.47-12.77%Miss-
    Mar 22
    Reported May 10
    		$-2.98$-0.51-484.31%Miss-
    Dec 21
    Reported Mar 28
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-5.19EV/EBITDA-2.11x
    Price/FCF-8.10xFCF Yield-12.35%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-50.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio14.32xQuick Ratio14.32x
    Trading Statistics
    Beta-0.99Avg Volume221.92K
    52-Week High$7.1952-Week Low$1.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.72
    SMA 20$5.84
    SMA 50$5.25
    SMA 200$3.29
    EMA 10$5.68
    EMA 20$5.65
    EMA 50$5.30
    EMA 200$3.76

    MACD

    Line: 0.10Signal: 0.18Hist: -0.08

    ADX

    ADX: 30.2+DI: 18.3-DI: 13.1

    Aroon & PSAR

    Aroon Up48.0
    Aroon Down4.0
    PSAR$6.44

    Bollinger Bands

    Upper Band$6.22
    Lower Band$5.46
    %B Position1313%(Upper)
    Band Width0.12

    RSI (14-Day)

    Neutral
    49.3

    Momentum Oscillators

    Stoch %K11.5
    Stoch %D10.0
    Williams %R-91.6
    ROC (10d)-3.1%
    Momentum-0.18
    CCI (20d)-145.2
    MFI (14d)27.8

    Volatility Measures

    ATR (14d)$0.38(6.9%)
    StdDev (20d)0.19
    Hist Vol54.3%(High)

    Volume Flow

    VWAP$5.53
    OBV76.1M
    AD Line23.1M
    CMF (20d)-0.132

    Volume Metrics

    Avg Vol (20d)217.7K
    Vol Ratio0.6x
    VWMA (20d)$5.86

    Pivot Points

    R3$6.15
    R2$5.97
    R1$5.77
    Pivot Point$5.59
    S1$5.39
    S2$5.21
    S3$5.01

    Advanced Oscillators

    TSI9.94
    Ultimate Osc46.3
    KST146.35

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$80,000$0
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0$40,000$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0$40,000$0
    Operating Expenses$8.90M$10.55M$9.32M$10.04M$7.22M$11.54M$8.60M$14.01M$15.88M$18.30M$18.82M$18.18M
    R&D$6.02M$6.74M$6.88M$7.00M$3.20M$7.69M$5.40M$8.29M$12.15M$14.65M$14.92M$14.43M
    SG&A$2.88M$3.81M$2.44M$3.04M$4.02M$3.85M$3.21M$3.48M$3.73M$3.64M$3.90M$3.75M
    Operating Income$-8,904,000$-10,551,000$-9,316,000$-10,040,000$-7,216,000$-11,537,000$-8,598,000$-14,014,000$-15,880,000$-18,296,000$-18,815,000$-18,180,000
    Interest Income$720,000$523,000$605,000$687,000$754,000$888,000$1.08M$1.27M$1.45M$1.68M$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-8,185,000$-10,028,000$-8,710,000$-9,353,000$-6,462,000$-10,649,000$-7,522,000$-12,747,000$-14,435,000$-16,617,000$-16,101,000$-16,707,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-8,185,000$-10,028,000$-8,710,000$-9,353,000$-6,462,000$-10,649,000$-7,522,000$-12,747,000$-14,435,000$-16,617,000$-16,898,000$-16,707,000
    EBITDA$-8,999,000$-10,632,000$-9,432,000$-10,251,000$-7,515,000$-11,980,000$-9,165,000$-14,745,000$-16,770,000$-19,386,000$-20,121,000$-17,360,000
    EBIT$-8,905,000$-10,551,000$-9,315,000$-10,040,000$-7,216,000$-11,537,000$-8,598,000$-14,014,000$-15,880,000$-18,295,000$-18,815,000$-16,707,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ANTX

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    N/A
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    0
    Avg Remaining Term
    1.9 mo

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    AN2 Therapeutics names Cameron Trenor as chief medical officer

    AN2 Therapeutics has announced the appointment of Cameron Trenor, M.D., as its new Chief Medical Officer. Dr. Trenor brings over 20 years of experience in clinical and translational development across various medical fields and previously held key roles at Cellarity and Forma Therapeutics. He will continue his practice as a pediatric hematologist-oncologist at Boston Children’s Hospital, and the company also acknowledged the contributions of co-founder Dr. George H. Talbot, who will continue as a strategic advisor.

    Investing.com•8/25/26•
    Bullish

    AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

    AN2 Therapeutics, Inc. (Nasdaq: ANTX) has announced the appointment of Cameron Trenor, M.D., as its new Chief Medical Officer. Dr. Trenor brings over two decades of experience in clinical, translational, and drug development across various therapeutic areas, including rare diseases, hematology, and oncology. His appointment is expected to be invaluable as the company continues to advance its pipeline of novel small molecule therapeutics.

    Business Wire•8/25/26•
    Bullish

    AN2 Therapeutics Names Dr. Cameron Trenor as Chief Medical Officer

    AN2 Therapeutics Inc., a clinical-stage biopharmaceutical company, has appointed Dr. Cameron Trenor as its Chief Medical Officer. Dr. Trenor brings over 20 years of experience in leading clinical and translational development programs across various therapeutic areas, previously holding key roles at Cellarity and Forma Therapeutics. His expertise in clinical organization building, innovative therapy development, and regulatory engagement will be crucial for advancing AN2 Therapeutics' pipeline.

    Contract Pharma•8/24/26•
    Bullish

    AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

    AN2 Therapeutics has announced the appointment of Cameron Trenor, M.D., as its new Chief Medical Officer. Dr. Trenor brings over two decades of experience in clinical, translational, and drug development leadership, having previously served as CMO at Cellarity and in key roles at Forma Therapeutics and Novartis. He will be instrumental in advancing AN2's pipeline, which focuses on novel small molecule therapeutics from its boron chemistry platform, with three Phase 2 studies expected in 2026.

    BioSpace•8/24/26•
    Bullish

    AN2 Therapeutics names Cameron Trenor as chief medical officer By Investing.com

    AN2 Therapeutics has appointed Cameron Trenor, M.D., as its new Chief Medical Officer. Dr. Trenor brings over 20 years of experience in clinical development across various therapeutic areas and previously held key roles at Cellarity and Forma Therapeutics. The company, focused on small molecule therapeutics from its boron chemistry platform, expects to have three Phase 2 studies active in 2026.

    Investing.com Nigeria•8/24/26•
    Bullish

    Frequently Asked Questions About ANTX

    Does ANTX pay dividends?
    AN2 Therapeutics Inc (ANTX) does not currently pay a regular dividend.
    What is ANTX's market cap?
    AN2 Therapeutics Inc (ANTX) has a market capitalization of $210.57M with a current stock price of $5.55.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In